Roivant Sciences Ltd. (ROIV) operates as a rather unconventional biopharmaceutical holding company, a sort of biotech venture capitalist with a penchant for medical alchemy. Instead of a monolithic R&D pipeline, Roivant's core business model involves identifying promising drug candidates—often those deprioritized or shelved by larger pharmaceutical entities—and then creating nimble, focused subsidiary companies, affectionately known as "vants," to develop and commercialize them. This unique "hub-and-spoke" structure allows each "vant" to operate with the agility of a startup, dedicating singular focus to one or two therapeutic assets, thereby attempting to transmute overlooked compounds into valuable medicines.

The company’s portfolio spans various therapeutic areas, primarily immunology and inflammation, with key products including LISRAYA™ (brepocitinib) for dermatomyositis, launched in 2026, and a stake in ARCALYST for recurrent pericarditis. While its earlier dermatology success, VTAMA (tapinarof), was developed by a subsidiary later sold, Roivant continues to advance a diversified pipeline with programs like batoclimab and RVT-3101. Operating globally with headquarters in New York and offices in Basel, Roivant’s competitive edge lies in its decentralized model, strategic partnerships, and efficient capital allocation, aiming to accelerate drug development. However, this model isn't without its dramatic flair; the company faced scrutiny over the spectacular failure of its Alzheimer's drug, intepirdine, under its Axovant subsidiary, which some critics dubbed a "discard-reliant pharma." More recently, Roivant secured a hefty $950 million settlement from Moderna in a patent dispute over lipid nanoparticle technology, proving that even in the high-stakes world of drug development, sometimes the best offense is a good legal defense.